Cart summary

You have no items in your shopping cart.

Cyclophosphamide hydrate

SKU: orb1224494

Description

A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities; used to treat cancers and autoimmune diseases.Chemotherapeutic Agents Approved(In Vitro):Cyclophosphamide induces outer membrane blebbing, leads to DNA fragmentation, as revealed by TUNEL staining of free 3'-OH DNA ends, and induces cleavage of the caspase 3 and caspase 7 substrate PARP in 9L/P450 cells. Bcl-2 expression fully blocks the activation of both initiator caspases as well as the effector caspase 3 in cells treated with activated Cyclophosphamide. Bcl-2 inhibits the cytotoxic effects but not the cytostatic effects of activated Cyclophosphamide. Cyclophosphamide inhibits the AChE reversibly with an IC50 of 511 μM. Carbon tetrachloride does not affect the direct cytotoxicity of cyclophosphamide or 4-hydroxycyclophosphamide to cells in culture.(In Vivo):Cyclophosphamide (injected i.p.;2mg/mouse in 0.1 mL PBS, in C3H mice bearing SW1 tumors) increases the percentage of cells that stained for CD3, CD4 or CD8 in both spleens and tumors.

Images & Validation

Key Properties

CAS Number6055-19-2
MW279.1012
Purity>98% (HPLC)
FormulaC7H17Cl2N2O3P
SMILESO.ClCCN(CCCl)P1(=O)NCCCO1
TargetDNA Alkylator
SolubilityDMSO: ≥ 38 mg/mL

Bioactivity

In Vivo
Cyclophosphamide (injected i.p.; 2mg/mouse in 0.1 mL PBS, in C3H mice bearing SW1 tumors) increases the percentage of cells that stained for CD3, CD4 or CD8 in both spleens and tumors. Animal model: Six to eight-week old female C3H/HeN mice bearing SW1 tumors. Dosage: 2 mg/mouse. Administration: Injected i.p.; 2mg/mouse in 0.1 mL PBS; Four days. Result: Increased the percentage of cells that stained for CD3, CD4 or CD8 in both spleens and tumors.
In Vitro
Cyclophosphamide induces outer membrane blebbing, leads to DNA fragmentation, as revealed by TUNEL staining of free 3'-OH DNA ends, and induces cleavage of the caspase 3 and caspase 7 substrate PARP in 9 L/P450 cells. Bcl-2 expression fully blocks the activation of both initiator caspases as well as the effector caspase 3 in cells treated with activated Cyclophosphamide. Bcl-2 inhibits the cytotoxic effects but not the cytostatic effects of activated Cyclophosphamide. Cyclophosphamide inhibits the AChE reversibly with an IC50 of 511 μM. Carbon tetrachloride does not affect the direct cytotoxicity of cyclophosphamide or 4-hydroxycyclophosphamide to cells in culture.

Storage & Handling

StorageStorage temperature: -20°C. Stability: ≥ 2 years
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

Cyclophosphamide monohydrate

Similar Products

Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Cyclophosphamide hydrate (orb1224494)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

50 mg
$ 70.00
100 mg
$ 90.00
200 mg
$ 100.00
500 mg
$ 130.00
1 g
$ 190.00
DispatchUsually dispatched within 5-10 working days
Bulk Enquiry